Europe
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis - EU Politics Today - EIN Presswire <div class="eh-ribbon"> Trusted News Since 1995 <span class="prof…
